Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Restore CFTR FunctionEnrolling Location: Australia

    A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation , protocol number NCT02742519 VX15-770-123

    A Phase 3b, 2-part, Randomized, Double-blind, Placebo-controlled Crossover Study With a Long-term Open-label Period to Investigate Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

    • Age:

      3-5 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: LOCATION: Perth Linear Clinical Research, Contact: Jennifer Seabourne CONTACT: [email protected] Brisbane-Q-pharm CONTACT: Sharon Rankine Phone: 0439 664 900,; Email: [email protected]

    A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants , protocol number NCT03173573 FDL176-2016-01

    This is a 5-part study. Part 1 is a double blind, placebo-controlled, dose escalation, first-in-human study to assess the safety, tolerability and PK profiles following single oral administration of FDL176 to healthy male participants. Part 2 is a single dose, open-label study in healthy male participants to determine the effect of food on the PK profile of FDL176. Part 3 is a single dose, double blind, placebo-controlled study in healthy female participants to assess the PK, safety and tolerability profiles of FDL176. Part 4 is a randomised, double-blind, placebo-controlled, dose-escalation study to assess the safety, tolerability and PK profiles following multiple oral administrations of FDL176 to healthy male and female participants. Part 5 is a single dose, open-label study in male and female participants with CF to determine the PK profile of FDL176.

    • Age:

      18 Years to 55 Years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Australia - QLD

    A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects , protocol number NCT03093714 FDL169-2015-04

    A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Safety, Pharmacokinetics (PK) and Pharmacodynamics(PD) of FDL169 in Cystic Fibrosis (CF) Subjects Homozygous for the F508del-CFTR Mutation

    • Age:

      18 Years to 85 Years

    • Mutation(s):

      Homozygous for the F508del-CFTR mutation.

    • FEV1% Predicted:

      (FEV1) >40% of predicted normal for age, sex and height.

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Australia

    Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) (SAPHIRA1) , protocol number NCT02707562

    A Phase IIa, Open-label Study of Multiple Doses of GLPG1837 in Subjects With Cystic Fibrosis and the G551D Mutation

    • Age:

      >18 years

    • Mutation(s):

      G551D

    • FEV1% Predicted:

      Pre- or post-bronchodilator FEV1 ≥ 40% of predicted normal

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Australia

    A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation , protocol number NCT02514473 VX14-809-109

    A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

    • Age:

      6-11 years

    • Mutation(s):

      homozygous for the F508del CFTR mutation

    • FEV1% Predicted:

      ppFEV1 of ≥70 p

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Queensland University of Technology Contact: Jeremy Russell - phone:07 3069 7552 email: [email protected] To get started, go to: https://rebrand.ly/HYPRS-CF

    Helping Young People Reduce the Stress of Cystic Fibrosis Study , protocol number The HYPRS-CF Study 1800000294 (UHREC Reference number)

    Researchers at QUT are conducting a national, online research study with young people with Cystic Fibrosis (CF). The goal of this study is to learn how young people think and feel about the stress of CF and whether a social robot could possibly help them cope with this stress.

    • Age:

      10-18 years

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      1

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Multiple care centres across the U.S.

    Study of VX-445 triple combination in teens and adults with cystic fibrosis who have one copy of F508del and one copy of a gating or residual function mutation , protocol number NCT04058353 VX18-445-104

    This study will look at the safety and effectiveness of three CFTR modulators when taken in combination: VX-445 (elexacaftor), tezacaftor and ivacaftor. CFTR modulators are drugs intended to help CFTR protein function closer to normal.

    • Age:

      12 Years and older

    • Mutation(s):

      One Copy F508del

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      8

    • Length of Participation:

      20 weeks

    Contact us about this clinical Trial >
  • Mucociliary ClearanceCompleted with results Location: Multiple care centres across the US

    Study of QBW276 in adults with CF , protocol number NCT92566044 NOVARTIS CQBW 276X2201

    This study evaluated the safety and tolerability of QBW276, an inhaled drug designed to improve mucus clearance. This study also evaluated how the body processes the drug.

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40 to 100%

    • Number of Visits:

      6

    • Length of Participation:

      14 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US

    Roll-over study of ivacaftor in children with CF who have a CFTR gating mutation (Vertex VX-770-109) , protocol number NCT01946412 VERTEX VX-770-109

    This study evaluated the long-term safety of ivacaftor (Kalydeco®) in children with CF. This study was for children who have a CFTR gating mutation and received at least one dose of ivacaftor in the VX11-770-108 study.

    • Age:

      2 years to 5 years

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      7

    • Length of Participation:

      88 weeks

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: Multiple care centres across the US

    Open-label study of ivacaftor in people with CF who have a non-G551D CFTR gating mutation (Vertex VX-770-112) , protocol number NCT01707290 VERTEX VX-770-112

    This study evaluated the long-term safety of ivacaftor (Kelydeco®) in participants who have a non-G551D CFTR gating mutation. This study was for people who had participated in one of the VX11-770-110, VX12-770111 or VX12-770-113 studies.

    • Age:

      6 Years and Older

    • Mutation(s):

      One Copy F508del or No Copies F508del

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      7

    • Length of Participation:

      2 years

    Contact us about this clinical Trial >
  • Displaying results 81-90 (of 193)
     |<  <  5 - 6 - 7 - 8 - 9 - 10 - 11 - 12 - 13 - 14  >  >|